FDA pharmacologic class
CD38-directed Cytolytic Antibody
2 medicines are in FDA's class of cd38-directed cytolytic antibodies: isatuximab (Sarclisa) and daratumumab (Darzalex); 1 combination product also contains one. 0 of the 3 are listed from generic labelers (FDA NDC Directory, October 8, 2026).
Which medicines are cd38-directed cytolytic antibody?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Isatuximab | Sarclisa | none listed | n/a | No | No current entry | 0 |
| Daratumumab | Darzalex | none listed | n/a | No | No current entry | 1 |
| Daratumumab and hyaluronidase | Darzalex | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)